#1 Clinical Trials Search in Europe

Emapalumab

Emapalumab is an innovative monoclonal antibody that targets and neutralizes interferon gamma (IFN-γ), a key cytokine involved in inflammation and immune responses. This article explores the ongoing clinical trials investigating emapalumab’s potential in treating various conditions, from rare diseases like hemophagocytic lymphohistiocytosis (HLH) to more common conditions like sepsis and cancer. These trials aim to assess the drug’s efficacy, safety, and optimal dosing regimens across different patient populations.

Table of Contents

What is Emapalumab?

Emapalumab is a medication that belongs to a class of drugs called monoclonal antibodies. It is also known by the brand name Gamifant[1]. Emapalumab is designed to target and neutralize a specific protein in the body called interferon gamma (IFN-γ)[2]. This protein plays a crucial role in certain inflammatory conditions, and by blocking its activity, emapalumab can help control excessive inflammation in the body.

How Does Emapalumab Work?

Emapalumab works by binding to and neutralizing interferon gamma (IFN-γ), a key protein that contributes to inflammation and tissue damage in certain rare disorders[1]. By blocking the activity of IFN-γ, emapalumab can help reduce inflammation and alleviate symptoms in patients with specific inflammatory conditions. This targeted approach makes emapalumab a promising treatment for disorders where excessive inflammation is a primary concern.

What Conditions Does Emapalumab Treat?

Emapalumab is being studied and used to treat several rare inflammatory disorders, including:

  • Hemophagocytic Lymphohistiocytosis (HLH): This is a rare, life-threatening condition characterized by uncontrolled inflammation. Emapalumab has been approved by the FDA for treating primary HLH in patients who have not responded to or cannot tolerate conventional treatments[2].
  • Macrophage Activation Syndrome (MAS): This is a severe complication that can occur in patients with systemic juvenile idiopathic arthritis (sJIA) or adult-onset Still’s disease (AOSD). Clinical trials are investigating the use of emapalumab in treating MAS[1].
  • Systemic Lupus Erythematosus (SLE): Research is ongoing to evaluate the effectiveness of emapalumab in treating MAS associated with SLE[3].
  • Graft Failure: Studies are exploring the potential of emapalumab in preventing graft failure after hematopoietic stem cell transplantation[4].
  • Sepsis: Researchers are investigating whether emapalumab can improve outcomes in patients with sepsis driven by excessive interferon gamma activity[5].

How is Emapalumab Administered?

Emapalumab is typically administered through intravenous (IV) infusion, which means it is given directly into a vein. The dosage and frequency of administration can vary depending on the specific condition being treated and the individual patient’s needs. In general, treatment regimens may include:

  • An initial higher dose followed by lower maintenance doses
  • Infusions given every 3-4 days or twice a week
  • Treatment duration ranging from a few weeks to several months, depending on the patient’s response and the condition being treated[1][2]

The exact dosing schedule will be determined by the healthcare provider based on the patient’s specific situation and response to treatment.

Current Clinical Trials

Emapalumab is currently being studied in several clinical trials to evaluate its effectiveness and safety in various conditions:

  • Treatment of MAS in patients with Still’s disease or systemic lupus erythematosus[3]
  • Prevention of graft failure in patients undergoing hematopoietic stem cell transplantation[4]
  • Management of sepsis driven by interferon gamma activity[5]
  • Treatment of prolonged cytopenia (low blood cell counts) after CAR T-cell therapy[6]
  • Prevention of CAR T-cell therapy-associated toxicities in patients with certain types of lymphoma[7]

Potential Side Effects

As with any medication, emapalumab can cause side effects. Common side effects reported in clinical trials include:

  • Infections
  • Fever
  • Infusion-related reactions
  • Changes in blood cell counts
  • Elevated liver enzymes

It’s important to note that the safety profile of emapalumab is still being studied in ongoing clinical trials. Patients should discuss potential risks and benefits with their healthcare provider[1][2].

Future Research and Applications

Researchers are exploring new potential applications for emapalumab, including:

  • Use in combination with other therapies to enhance treatment effectiveness
  • Application in other inflammatory or autoimmune conditions
  • Development of imaging techniques using emapalumab to visualize interferon gamma activity in the body[8]

As research continues, our understanding of emapalumab and its potential benefits in treating various inflammatory conditions is likely to expand.

Aspect Details
Drug Name Emapalumab (also known as NI-0501, Gamifant)
Drug Type Monoclonal antibody targeting interferon gamma (IFN-γ)
Main Conditions Studied Hemophagocytic Lymphohistiocytosis (HLH), Macrophage Activation Syndrome (MAS), Graft Failure, Sepsis, Cytopenia
Administration Intravenous infusion, typically 6 mg/kg initial dose, followed by 3 mg/kg maintenance doses
Primary Outcomes Overall response rates, disease-specific score improvements, survival rates, safety profile
Secondary Outcomes Pharmacokinetics, biomarker levels, quality of life, specific clinical improvements
Safety Monitoring Adverse events, infections, laboratory parameter changes
Novel Applications Potential use as an imaging agent in cancer (when labeled with Zirconium-89)

FAQ

  • What is emapalumab and how does it work? Emapalumab is a fully human monoclonal antibody that binds to and neutralizes interferon gamma (IFN-γ). It works by blocking both soluble and receptor-bound forms of IFN-γ, which is a key cytokine involved in inflammation and immune responses. By neutralizing IFN-γ, emapalumab aims to reduce excessive inflammation and tissue damage in various conditions.
  • What conditions are being studied for emapalumab treatment? Clinical trials are investigating emapalumab for several conditions, including hemophagocytic lymphohistiocytosis (HLH), macrophage activation syndrome (MAS), graft failure in stem cell transplantation, sepsis, cytopenia associated with CAR T-cell therapy, and as a potential imaging agent in non-small cell lung cancer.
  • How is emapalumab administered in clinical trials? Emapalumab is typically administered through intravenous (IV) infusion. The dosing regimens vary across trials, but often include an initial higher dose followed by regular maintenance doses. For example, one common regimen is 6 mg/kg initially, followed by 3 mg/kg doses every 3-4 days.
  • What are the main outcomes being measured in emapalumab trials? The primary outcomes often include overall response rates, changes in disease-specific scores (e.g., SOFA score in sepsis), survival rates, and safety profiles. Secondary outcomes may include pharmacokinetics, biomarker levels, quality of life assessments, and specific clinical improvements related to the condition being studied.
  • Are there any known side effects of emapalumab? While the safety profile is still being fully established through clinical trials, emapalumab appears to be generally well-tolerated. Researchers are monitoring for adverse events, including potential increased risk of infections due to its immunomodulatory effects. The trials include careful safety monitoring and reporting of all adverse events.

Ongoing Clinical Trials on Emapalumab

  • Study of emapalumab in children and adults with Macrophage Activation Syndrome (MAS) occurring in Still’s Disease or Systemic Lupus Erythematosus

    Not recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Czechia Italy The Netherlands

  • Study on Emapalumab for Patients with Sepsis Linked to Interferon-Gamma

    Not recruiting

    1 1
    Investigated diseases:
    Investigated drugs:
    Greece

Glossary

  • Emapalumab: A fully human monoclonal antibody that targets and neutralizes interferon gamma (IFN-γ), used to treat certain inflammatory and immune-related conditions.
  • Hemophagocytic Lymphohistiocytosis (HLH): A rare, life-threatening condition characterized by excessive immune activation and inflammation, which can lead to organ damage if left untreated.
  • Macrophage Activation Syndrome (MAS): A severe complication of rheumatic diseases, particularly systemic juvenile idiopathic arthritis, characterized by excessive activation and proliferation of T lymphocytes and macrophages.
  • Interferon Gamma (IFN-γ): A cytokine that plays a crucial role in immune responses, particularly in activating macrophages and promoting inflammation.
  • Monoclonal Antibody: A type of protein made in the laboratory that can bind to substances in the body, including cancer cells. They are used to treat various diseases, including some types of cancer.
  • Pharmacokinetics (PK): The study of how a drug is absorbed, distributed, metabolized, and eliminated by the body over time.
  • Pharmacodynamics (PD): The study of the biochemical and physiological effects of drugs on the body, including their mechanisms of action and the relationship between drug concentration and effect.
  • SOFA Score: Sequential Organ Failure Assessment score, a scoring system used to determine the extent of a person's organ function or rate of failure in intensive care units.
  • Cytokine: Small proteins released by cells that have specific effects on the interactions and communications between cells, particularly in immune responses.
  • Biomarker: A measurable indicator of some biological state or condition, often used to assess the presence or progress of a disease or the effects of a treatment.

References

  1. https://clinicaltrials.gov/study/NCT03311854
  2. https://clinicaltrials.gov/study/NCT03985423
  3. https://clinicaltrials.gov/study/NCT05001737
  4. https://clinicaltrials.gov/study/NCT04731298
  5. https://clinicaltrials.gov/study/NCT06694701
  6. https://clinicaltrials.gov/study/NCT06285825
  7. https://clinicaltrials.gov/study/NCT06550141
  8. https://clinicaltrials.gov/study/NCT06439914